Taking account of the crucial function of SET domain in SETD2, we predicted that mutations at the SET domain might result in the loss of methyltransferases features of SETD2 and poor prognosis of ccRCC patients. This evidence concerns the gene SET and nonpapillary renal cell carcinoma.